Our gastrointestinal tract is home to trillions of bacteria that play a crucial role in the digestion of food and maintaining our overall health and wellbeing. However, when the harmful bacteria in our gut outnumber the beneficial ones, it leads to a state of dysbiosis, which is associated with various common and chronic illnesses, such as obesity, diabetes, functional and inflammatory bowel disorders (IBS and IBD), neurological conditions (e.g., multiple sclerosis, myalgic encephalomyelitis/chronic fatigue syndrome, autism), certain types of cancer, and mental health disorders.
A healthy gut microbiota is characterized by a diverse and thriving community of microorganisms. However, our modern lifestyle, unbalanced diet, excessive use of antibiotics, and stress can disrupt this delicate balance.
There is mounting evidence highlighting the crucial role of gut microbiota in several complex diseases, leading to the development of a new class of products and therapeutics that target the microbiome. ImmuneBiotech is among the leading players in this field.
Dysbiosis not only alters the intestinal permeability, causing a “leaky gut,” but also affects the mucosal immune system, leading to inflammation in both the local and distal areas. This disturbance in the microbiota equilibrium contributes to the pathogenesis of various diseases. ImmuneBiotech considers all these factors during the scientific screening and precision in selection and development of its probiotic products.